Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 23
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Axsome Therapeutics Inc
AXSM
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$145.04
-11.03
-7.07%
Últ. Act.: Oct 23, 5:13 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Ganancias:
Beneficios de Q3 2026 dentro de 10 días de ahora en lun nov 2nd, antes de la apertura del mercado
Axsome Therapeutics Financials
Axsome Therapeutics (AXSM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results
Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.
Avi Kapoor
PRO
Axsome Therapeutics Q2 EPS $(0.99) Misses $(0.83) Estimate, Sales $218.400M Miss $221.230M Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.83) by 19.28 percent. This is a 110.64 percent decrease over losses of $(0.47) per
Benzinga Newsdesk
Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock
Axsome (AXSM) Q1: Revenue beats, but wider loss and rising expenses weigh on shares. Get the key data on Sunosi and Auvelity sales.
Vandana Singh
Earnings Scheduled For May 4, 2026
Benzinga Insights
PRO
Axsome Therapeutics Q1 EPS $(1.26) Misses $(0.90) Estimate, Sales $191.203M Beat $189.193M Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.90) by 40 percent. This is a 85.29 percent decrease over losses of $(0.68) per share
Benzinga Newsdesk
PRO
Axsome Therapeutics Q4 EPS $(0.56) Beats $(0.68) Estimate, Sales $195.999M Beat $193.107M Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.68) by 17.4 percent. This is a 30 percent increase over losses of $(0.80) per share from
Benzinga Newsdesk
